Iovance Biotherapeutics (IOVA)
Commercializes TIL cell therapies for melanoma and other solid-tumor settings.
$10.29
vs last close−0.36 (−3.34%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 31 | 59 | 74 | 49 | 60 | 67 | 87 | 71 | 99 |
| Cost of revenue | 4 | 4 | 7 | 31 | 40 | 46 | 50 | 57 | 1 | −101 | 1 | 45 |
| Gross profit | −4 | −4 | −7 | 0 | 19 | 28 | 0 | 3 | 66 | 187 | 70 | 54 |
| 114 | 117 | 111 | 102 | 108 | 115 | 121 | 117 | 161 | 261 | 151 | 106 | |
| Research & development | 88 | 87 | 80 | 62 | 68 | 72 | 77 | 79 | 75 | 69 | 62 | 64 |
| 27 | 30 | 26 | 34 | 40 | 43 | 44 | 38 | 35 | 36 | 39 | 0 | |
| Selling & marketing | 0 | 0 | 18 | 0 | 0 | 0 | 33 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 8 | 0 | 40 | 0 | 11 | 0 | 0 | 0 | 0 | 0 |
| Other expenses | 0 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 51 | 156 | 50 | 42 |
| Operating income | −118 | −121 | −118 | −102 | −89 | −87 | −121 | −114 | −95 | −73 | −81 | −52 |
| 3 | 3 | 3 | 3 | 4 | 10 | 3 | 4 | 1 | 2 | 1 | 3 | |
| Interest income | 3 | 3 | 3 | 3 | 4 | 10 | 3 | 4 | 0 | 7 | 1 | 0 |
| Other non-operating income | 0 | −3 | −3 | −3 | 0 | −10 | −3 | −4 | −1 | −2 | −1 | −3 |
| Income before tax | −115 | −118 | −114 | −99 | −85 | −77 | −118 | −110 | −94 | −72 | −80 | −49 |
| Income tax expense | −1 | −2 | −1 | −1 | −2 | 2 | −2 | 2 | −2 | 0 | −1 | −1 |
| Net income from continuing operations | −114 | −116 | −113 | −97 | −84 | −79 | −116 | −112 | −91 | −72 | −79 | −47 |
| Net income | −114 | −116 | −113 | −97 | −84 | −79 | −116 | −112 | −91 | −72 | −79 | −47 |
| EPS, basic | −$0.46 | −$0.45 | −$0.42 | −$0.34 | −$0.28 | −$0.26 | −$0.36 | −$0.33 | −$0.25 | −$0.15 | −$0.19 | −$0.11 |
| EPS, diluted | −$0.46 | −$0.45 | −$0.42 | −$0.34 | −$0.28 | −$0.26 | −$0.36 | −$0.33 | −$0.25 | −$0.15 | −$0.19 | −$0.11 |
| Weighted average shares, basic | 246 | 256 | 266 | 285 | 303 | 305 | 323 | 335 | 364 | 407 | 419 | 450 |
| Weighted average shares, diluted | 246 | 256 | 266 | 285 | 303 | 305 | 323 | 335 | 364 | 407 | 419 | 450 |
| EBITDA | −108 | −108 | −104 | −88 | −78 | −65 | −107 | −98 | −85 | −68 | −71 | −39 |
| Depreciation & amortization | 10 | 10 | 10 | 11 | 11 | 12 | 11 | 12 | 9 | 4 | 9 | 10 |
| EBIT | −118 | −118 | −114 | −99 | −89 | −77 | −118 | −110 | −94 | −72 | −80 | −49 |
